Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Sales | 5,602,000 | 5,957,401 | 5,443,300 | 5,600,700 | 5,602,000 |
| Cost of Goods | 1,158,300 | 1,248,300 | 1,203,600 | 1,146,700 | 1,197,900 |
| Gross Profit | 4,443,700 | 4,709,100 | 4,239,700 | 4,454,000 | 4,404,100 |
| Operating Expenses | 3,000,400 | 3,698,200 | 3,100,800 | 3,252,500 | 3,023,700 |
| Operating Income | 1,443,600 | 1,011,201 | 1,139,500 | 1,202,200 | 1,381,300 |
| Other Income | 507,500 | 1,299 | 735,200 | -16,500 | -46,000 |
| Pre-tax Income | 1,951,100 | 1,012,500 | 1,874,700 | 1,185,700 | 1,335,300 |
| Income Tax | 403,100 | 185,200 | 548,100 | 262,100 | 324,200 |
| Net Income Continuous | 1,548,000 | 827,300 | 1,326,600 | 923,600 | 1,011,100 |
| Net Income | $1,548,000 | $827,300 | $1,326,600 | $923,600 | $1,011,100 |
| EPS Basic Total Ops | 1.42 | 0.75 | 1.18 | 0.83 | 0.91 |
| EPS Basic Continuous Ops | 1.42 | 0.74 | 1.19 | 0.83 | 0.91 |
| EPS Diluted Total Ops | 1.42 | 0.74 | 1.18 | 0.83 | 0.91 |
| EPS Diluted Continuous Ops | 1.42 | 0.74 | 1.18 | 0.83 | 0.91 |
| EBITDA(a) | $1,825,100 | $1,355,802 | $1,509,200 | $1,564,200 | $1,767,200 |